BioSpace News Archive

For Cold Spring Harbor Laboratory Research Professor Alexander Krasnitz, the answers may lie deep within vast databases and hospital archives containing hundreds of thousands of tumor samples.

PeptiDream Inc. announced a new multi-target collaboration and license Agreement with U.S.-based Merck & Co, Inc., Rahway, N.J., U.S.A., known as “MSD” outside the U.S. and Canada, through a subsidiary, focused on the discovery and development of novel peptide drug conjugates.

ZielBio, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead program, ZB131, for the treatment of treatment of pancreatic cancer, a rare solid-tumor cancer originating from the pancreas.

Novocure announced it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023.

Novadip Biosciences SA announced the appointment of Judy Ashworth, MD, as Chief Medical Officer of the Company.

SI-BONE, Inc., a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announced an additional FDA clearance for iFuse Bedrock Granite®.

ALR Technologies SG Ltd., the diabetes management company, announced the completion of a long-term manufacturing and supply agreement with Infinovo Medical Co. Ltd for the Continuous Glucose Monitor hardware used in the GluCurve Pet CGM.

NANOBIOTIX announced the first patient in the United States has been randomized in NANORAY-312, a global Phase 3 registrational trial evaluating NBTXR3 for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma who are ineligible for platinum-based chemotherapy.

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that the U.S. Food and Drug Administration has granted a Type A meeting to discuss the contents of a refusal to file letter previously issued regarding the company’s New Biologics License Application for NurOwn® for the treatment of ALS.

Koya Medical, a healthcare company on a mission to transform lymphatic and venous care through a comprehensive suite of innovative, people-centric platforms, announced the addition of Dr. Thomas Maldonado as Chief Medical Officer.